These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9187529)

  • 1. Mortality associated with selegiline in Parkinson's disease. What do the available data mean?
    Mizuno Y; Kondo T
    Drug Saf; 1997 May; 16(5):289-94. PubMed ID: 9187529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selegiline in Parkinson's disease.
    Calne DB
    BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of Parkinson's disease.
    Eadie MJ
    Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa.
    Przuntek H; Conrad B; Dichgans J; Kraus PH; Krauseneck P; Pergande G; Rinne U; Schimrigk K; Schnitker J; Vogel HP
    Eur J Neurol; 1999 Mar; 6(2):141-50. PubMed ID: 10053226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Churchyard A; Mathias CJ; Boonkongchuen P; Lees AJ
    J Neurol Neurosurg Psychiatry; 1997 Aug; 63(2):228-34. PubMed ID: 9285463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
    Olanow CW; Godbold JH; Koller W
    BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
    [No Abstract]   [Full Text] [Related]  

  • 14. Controversies in the treatment of Parkinson's disease.
    Hely MA; Morris JG
    Curr Opin Neurol; 1996 Aug; 9(4):308-13. PubMed ID: 8858190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug therapy of Parkinson's disease].
    Myllylä V
    Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract]   [Full Text] [Related]  

  • 16. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoamine oxidase inhibitors--is it time to up the TEMPO?
    Rascol O
    Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.